$844.6 Bn Recombinant DNA Technology Market Analysis to 2025 – Therapeutic Agent, Vaccine, Biotech Crops, Specialty Chemicals – Research and Markets

DUBLIN–(BUSINESS WIRE)–The "Recombinant
DNA Technology Market Analysis by Product (Therapeutic Agent, Vaccine,
Biotech Crops, Specialty Chemicals), by Component, by Application, by
End-use and Segment Forecasts, 2014 – 2025" report has been
added to Research and Markets' offering.

The global recombinant DNA technology market is expected to reach USD
844.6 billion by 2025.

Success of genetically engineered human insulin in diabetes treatment
has triggered the development of many other recombinant therapeutics and
drugs. This has translated to the huge success of Recombinant DNA (rDNA)
technology. This technology has offered significant prospects for
elucidating the gap between disease and its effective treatment.

Widespread successful application of this technique in veterinary
product development, genetically modified crop development, bio
pesticides & biofuel production, and gene therapy, are expected to spur
the adoption of this technology throughout the forecast period.

Use of Genetically Modified (GM) products, such as GM animals, developed
using rDNA method are found to be indispensable to accelerate medical
research. Furthermore, more than 3000 scientific studies have been
carried out to assess the GM products safety in context to its impact on
human health and environment.

In addition, there is rising need to improve the recombinant proteins'
production capacity by several folds, owing to increase in demand for
effective therapeutics for disease treatment. The aforementioned fact
pronounces the technological advances in this sector thus driving growth.

As per Monsanto and other proponents of GM crops, genetic engineering is
one of the fastest and widely adopted agricultural innovations over the
past few years. This, in turn, is expected bolster the adoption of rDNA
technology for non-traditional applications.

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Market Variables, Trends & Scope

Chapter 4 Product Estimates & Trend Analysis

Chapter 5 Component Estimates & Trend Analysis

Chapter 6 Application Estimates & Trend Analysis

Chapter 7 End-use Estimates & Trend Analysis

Chapter 8 Regional Estimates & Trend Analysis, by Product, Component,
Application, & End-use

Chapter 9 Competitive Landscape

• Monsanto Company
• F. Hoffmann-La Roche Ltd
• Biogen
• Amgen Inc
• Novartis AG
• Eli Lilly and Company
• GenScript
• Pfizer Inc.
• Novo Nordisk A/S
• Sanofi
• Merck KGaA
• Profacgen
• Biocon
• GlaxoSmithKline plc.
• Cibus
• Horizon Discovery Group plc
• New England Biolabs

For more information about this report visit https://www.researchandmarkets.com/research/kv278v/recombinant_dna

About Research and Markets

Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.

Contacts

Research and Markets
Laura Wood, Senior Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Genomics